A Phase 2/3 interventional study of SD-809 and Placebo in Tardive Dyskinesia, sponsored by Auspex Pharmaceuticals, Inc.. Completed at 41 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-11-09.
Sponsored by Auspex Pharmaceuticals, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Tardive Dyskinesia with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Tardive Dyskinesia · United States.
Among the 31 studies in Tardive Dyskinesia with a site in United States, this one is the 9th largest by enrollment of the 27 interventional ones that give a count, is one of 5 that started in 2014, is the only one in phase 2/3, and was the 11th registered.
62 studies on the registry are indexed under Tardive Dyskinesia; 9 are open to participants now.
Browse Tardive Dyskinesia studies →6 of the 31 studies in Tardive Dyskinesia with a site in United States are open now. Recruiting first, the newest first:
University Hospitals Cleveland Medical Center · Sites in United States
Ages 18–89
Neurocrine Biosciences · Sites in United States, Bulgaria, Puerto Rico
Ages 18–75
Neurocrine Biosciences · Sites in United States
Ages 18+
iRxReminder · Sites in United States
Ages 18+
Corporal Michael J. Crescenz VA Medical Center · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 7 Tardive Dyskinesia studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 7 · Phase 4 8
First in 1996; this study’s year is marked. 5 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 117 is above the median of 60 across 51 interventional studies indexed under Tardive Dyskinesia.
Median enrollment 89 across the 27 interventional studies, 70 across the 3 observational. Of the 21 that completed or were terminated, 14 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 31 have an industry lead sponsor. The 10 most frequent:
This study is registered under Auspex Pharmaceuticals, Inc., one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Auspex Pharmaceuticals, Inc. is the lead sponsor of 5 studies on the registry; none are open to participants now.
Teva Pharmaceutical Industries, Ltd. has 3 studies filed under Tardive Dyskinesia — fewer than ten, so there is no comparison to draw.
2 of the studies in Tardive Dyskinesia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07365462Neurocrine BiosciencesEfficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia | 2027-02 |
| NCT06997198University Hospitals Cleveland Medical CenterDeutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities | 2027-10-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 31 studies in Tardive Dyskinesia with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether an investigational drug, SD-809 (deutetrabenazine), will reduce the severity of abnormal involuntary movements of tardive dyskinesia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SD-809 tablets taken twice daily for 12 weeks.
Drug: SD-809
Placebo tablets taken twice daily for 12 weeks.
Drug: Placebo
SD-809 tablets taken twice daily for 12 weeks, includes a dose titration period and maintenance period.
Also known as: deutetrabenazine, AUSTEDO®
Placebo tablets taken twice daily for 12 weeks.
Change in Centrally Read Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using Mixed Model Repeated Measures (MMRM) Analysis
AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and scored items. AIMS was digitally video recorded using a standard protocol and independently reviewed by blinded central raters who were experts in movement disorders. This outcome sums items 1 through 7 which cover orofacial movements, and extremity and truncal dyskinesia. Severity ratings were from 0 (none) to 4 (severe) for a total scale of 0 (no orofacial, truncal, and extremity dyskinesia) to 28 (severe orofacial, truncal, and extremity dyskinesia). A negative change from baseline score indicates improvement. A MMRM analysis with change from baseline in AIMS score as dependent variable was used. The model included fixed effects for treatment, time point, treatment-by-time point interaction, DRA status, and baseline AIMS as a covariate. An unstructured covariance model was used.
Time frame: Day 0 (Baseline), Weeks 2, 4, 6, 9 and 12
Percentage of Patients Who Are a Treatment Success at Week 12 as Assessed by the Clinical Global Impression of Change (CGIC)
The CGIC is a single-item questionnaire that asks the investigator to assess a patient's TD symptoms at specific visits after initiating therapy. The CGIC uses a 7 point Likert Scale, ranging from very much worse (-3) to very much improved (+3), to assess overall response to therapy. A treatment success was defined as "much improved" or "very much improved" at the week 12 visit. Patients whose status at week 12 was not known, as well as patients who were not "much improved" or "very much improved" at the week 12 visit, were considered treatment failures.
Time frame: Week 12
Percentage of Patients Who Are a Treatment Success at Week 12 as Assessed by the Patient Global Impression of Change (PGIC)
The PGIC is a single-item questionnaire that asks the patient to assess their TD symptoms at specific visits after initiating therapy. The PGIC uses a 7 point Likert Scale, ranging from very much worse (-3) to very much improved (+3), to assess overall response to therapy. A treatment success was defined as "much improved" or "very much improved" at the week 12 visit. Patients whose status at week 12 was not known, as well as patients who were not "much improved" or "very much improved" at the week 12 visit, were considered treatment failures.
Time frame: Week 12
Change From Baseline to Week 12 in the Modified Craniocervical Dystonia Questionnaire (CDQ-24)
The CDQ-24 is a disease-specific quality of life questionnaire developed for use in patients with craniocervical dystonia, including both cervical dystonia (CD) and blepharospasm (BPS). The CDQ 24 was modified such that the questions focus more directly on the impact of TD (as opposed to CD/BPS) on quality of life. The following domains are evaluated in the CDQ-24: stigma, emotional well-being, pain, activities of daily living, and social/family life. Each of the 24 questions were rated by patients on a scale of 0=no impairment to 4=severest impairment for a total scale of 0 (no impairment) to 96 (severe impairment). Negative change from baseline scores indicate improvement.
Time frame: Day 0 (Baseline), Week 12 with last observation carried forward
Participants With Adverse Events for the Overall Treatment Period
An adverse event was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relation of AE to treatment was determined by the investigator and includes possibly, probably and definitely related categories. Serious AEs (SAE) include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.
Time frame: Day 1 to Week 12
Percentage Change in Centrally Read Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using MMRM Analysis
AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and scored items. AIMS was digitally video recorded using a standard protocol and independently reviewed by blinded central raters who were experts in movement disorders. This outcome sums items 1 through 7 which cover orofacial movements, and extremity and truncal dyskinesia. Severity ratings were from 0 (none) to 4 (severe) for a total scale of 0 (no orofacial, truncal, and extremity dyskinesia) to 28 (severe orofacial, truncal, and extremity dyskinesia). A negative percent change from baseline score indicates improvement. The MMRM model includes fixed effects for treatment, time point (weeks 2, 4, 6, 9, 12), treatment-by-time point interaction, DRA status, and baseline AIMS as a covariate. Patient is a random effect.
Time frame: Day 0 (Baseline), Weeks 2, 4, 6, 9 and 12
Cumulative Percentage of Abnormal Involuntary Movement Scale (AIMS) Responders by Response Level (Percentage Improvement From Baseline) at Week 12
Response level represents the % improvement in AIMS from baseline. AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and scored items. AIMS was digitally video recorded using a standard protocol and independently reviewed by blinded central raters who were experts in movement disorders. This outcome sums items 1 through 7 which cover orofacial movements, and extremity and truncal dyskinesia. Severity ratings were from 0 (none) to 4 (severe) for a total scale of 0 (no orofacial, truncal, and extremity dyskinesia) to 28 (severe orofacial, truncal, and extremity dyskinesia). Patients with a missing AIMS score were considered to be AIMS nonresponders.
Time frame: Day 0 (Baseline), Week 12
Change in Locally Read Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using MMRM Analysis
This outcome is similar to the primary outcome except that AIMS was read locally. AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and scored items. This outcome reports the local reading of AIMS data. This outcome sums items 1 through 7 which cover orofacial movements, and extremity and truncal dyskinesia. Severity ratings were from 0 (none) to 4 (severe) for a total scale of 0 (no orofacial, truncal, and extremity dyskinesia) to 28 (severe orofacial, truncal, and extremity dyskinesia). A negative change from baseline score indicates improvement. A MMRM analysis with change from baseline in AIMS score as dependent variable was used. The model included fixed effects for treatment, time point (weeks 2, 4, 6, 9, and 12), treatment-by-time point interaction, DRA status, and baseline AIMS as a covariate.
Time frame: Day 0 (Baseline), Weeks 2, 4, 6, 9 and 12
| Milestone | SD-809 | Placebo |
|---|---|---|
| Started | 58 | 59 |
| Safety and itt populations | 58 | 59 |
| Modified itt population | 56 | 57 |
| Maintenance period | 53 | 54 |
| Completed | 52 | 52 |
| Not completed | 6 | 7 |
| Withdrew: Protocol violation | 0 | 2 |
| Withdrew: Noncompliance | 1 | 0 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Withdrawal by subject | 3 | 2 |
| Withdrew: Lost to follow-up | 1 | 1 |
AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and scored items. AIMS was digitally video recorded using a standard protocol and independently reviewed by blinded central raters who were experts in movement disorders. This outcome sums items 1 through 7 which cover orofacial movements, and extremity and truncal dyskinesia. Severity ratings were from 0 (none) to 4 (severe) for a total scale of 0 (no orofacial, truncal, and extremity dyskinesia) to 28 (severe orofacial, truncal, and extremity dyskinesia). A negative change from baseline score indicates improvement. A MMRM analysis with change from baseline in AIMS score as dependent variable was used. The model included fixed effects for treatment, time point, treatment-by-time point interaction, DRA status, and baseline AIMS as a covariate. An unstructured covariance model was used.
| units on a scale | SD-809 | Placebo |
|---|---|---|
| Change in Centrally Read Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using Mixed Model Repeated Measures (MMRM) Analysis | -3.0 ± 0.45 | -1.6 ± 0.46 |
The CGIC is a single-item questionnaire that asks the investigator to assess a patient's TD symptoms at specific visits after initiating therapy. The CGIC uses a 7 point Likert Scale, ranging from very much worse (-3) to very much improved (+3), to assess overall response to therapy. A treatment success was defined as "much improved" or "very much improved" at the week 12 visit. Patients whose status at week 12 was not known, as well as patients who were not "much improved" or "very much improved" at the week 12 visit, were considered treatment failures.
| percentage of participants | SD-809 | Placebo |
|---|---|---|
| Percentage of Patients Who Are a Treatment Success at Week 12 as Assessed by the Clinical Global Impression of Change (CGIC) | 48.2 | 40.4 |
The PGIC is a single-item questionnaire that asks the patient to assess their TD symptoms at specific visits after initiating therapy. The PGIC uses a 7 point Likert Scale, ranging from very much worse (-3) to very much improved (+3), to assess overall response to therapy. A treatment success was defined as "much improved" or "very much improved" at the week 12 visit. Patients whose status at week 12 was not known, as well as patients who were not "much improved" or "very much improved" at the week 12 visit, were considered treatment failures.
| percentage of participants | SD-809 | Placebo |
|---|---|---|
| Percentage of Patients Who Are a Treatment Success at Week 12 as Assessed by the Patient Global Impression of Change (PGIC) | 42.9 | 29.8 |
The CDQ-24 is a disease-specific quality of life questionnaire developed for use in patients with craniocervical dystonia, including both cervical dystonia (CD) and blepharospasm (BPS). The CDQ 24 was modified such that the questions focus more directly on the impact of TD (as opposed to CD/BPS) on quality of life. The following domains are evaluated in the CDQ-24: stigma, emotional well-being, pain, activities of daily living, and social/family life. Each of the 24 questions were rated by patients on a scale of 0=no impairment to 4=severest impairment for a total scale of 0 (no impairment) to 96 (severe impairment). Negative change from baseline scores indicate improvement.
| units on a scale | SD-809 | Placebo |
|---|---|---|
| Change From Baseline to Week 12 in the Modified Craniocervical Dystonia Questionnaire (CDQ-24) | -11.1 ± 2.14 | -8.3 ± 2.31 |
An adverse event was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relation of AE to treatment was determined by the investigator and includes possibly, probably and definitely related categories. Serious AEs (SAE) include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.
| Participants | SD-809 | Placebo |
|---|---|---|
| Overall Treatment Period: any AE | 41 | 36 |
| Overall Treatment Period: SAE | 3 | 5 |
| Overall Treatment Period: Severe AE | 3 | 3 |
| Overall Treatment Period: treatment-related AE | 28 | 21 |
| Overall Treatment Period: Deaths | 0 | 0 |
AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and scored items. AIMS was digitally video recorded using a standard protocol and independently reviewed by blinded central raters who were experts in movement disorders. This outcome sums items 1 through 7 which cover orofacial movements, and extremity and truncal dyskinesia. Severity ratings were from 0 (none) to 4 (severe) for a total scale of 0 (no orofacial, truncal, and extremity dyskinesia) to 28 (severe orofacial, truncal, and extremity dyskinesia). A negative percent change from baseline score indicates improvement. The MMRM model includes fixed effects for treatment, time point (weeks 2, 4, 6, 9, 12), treatment-by-time point interaction, DRA status, and baseline AIMS as a covariate. Patient is a random effect.
| percentage change | SD-809 | Placebo |
|---|---|---|
| Percentage Change in Centrally Read Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using MMRM Analysis | -26.7 ± 6.06 | -15.5 ± 6.26 |
Response level represents the % improvement in AIMS from baseline. AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and scored items. AIMS was digitally video recorded using a standard protocol and independently reviewed by blinded central raters who were experts in movement disorders. This outcome sums items 1 through 7 which cover orofacial movements, and extremity and truncal dyskinesia. Severity ratings were from 0 (none) to 4 (severe) for a total scale of 0 (no orofacial, truncal, and extremity dyskinesia) to 28 (severe orofacial, truncal, and extremity dyskinesia). Patients with a missing AIMS score were considered to be AIMS nonresponders.
| percentage of participants | SD-809 | Placebo |
|---|---|---|
| >=10% | 69.6 | 42.1 |
| >=20% | 50.0 | 29.8 |
| >=30% | 46.4 | 24.6 |
| >=40% | 32.1 | 22.8 |
| >=50% | 23.2 | 17.5 |
| >=60% | 19.6 | 8.8 |
| >=70% | 10.7 | 1.8 |
| >=80% | 8.9 | 1.8 |
| >=90% | 3.6 | 1.8 |
This outcome is similar to the primary outcome except that AIMS was read locally. AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and scored items. This outcome reports the local reading of AIMS data. This outcome sums items 1 through 7 which cover orofacial movements, and extremity and truncal dyskinesia. Severity ratings were from 0 (none) to 4 (severe) for a total scale of 0 (no orofacial, truncal, and extremity dyskinesia) to 28 (severe orofacial, truncal, and extremity dyskinesia). A negative change from baseline score indicates improvement. A MMRM analysis with change from baseline in AIMS score as dependent variable was used. The model included fixed effects for treatment, time point (weeks 2, 4, 6, 9, and 12), treatment-by-time point interaction, DRA status, and baseline AIMS as a covariate.
| units on a scale | SD-809 | Placebo |
|---|---|---|
| Change in Locally Read Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using MMRM Analysis | -4.9 ± 0.64 | -3.7 ± 0.65 |
Collected over Day 1 to Week 12. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SD-809 | 0/58 (0%) | 3/58 (5.2%) | 24/58 (41.4%) |
| Placebo | 0/59 (0%) | 5/59 (8.5%) | 26/59 (44.1%) |
| Event | SD-809 | Placebo |
|---|---|---|
| PneumoniaInfections and infestations | 1/58 | 1/59 |
| SchizophreniaPsychiatric disorders | 1/58 | 0/59 |
| ManiaPsychiatric disorders | 1/58 | 0/59 |
| Abscess jawInfections and infestations | 0/58 | 1/59 |
| OverdoseInjury, poisoning and procedural complications | 0/58 | 1/59 |
| Jaw fractureInjury, poisoning and procedural complications | 0/58 | 1/59 |
| Laryngeal hypertrophyRespiratory, thoracic and mediastinal disorders | 0/58 | 1/59 |
| Event | SD-809 | Placebo |
|---|---|---|
| SomnolenceNervous system disorders | 8/58 | 6/59 |
| Dry mouthGastrointestinal disorders | 2/58 | 6/59 |
| HeadacheNervous system disorders | 3/58 | 6/59 |
| FatigueGeneral disorders | 4/58 | 5/59 |
| InsomniaPsychiatric disorders | 4/58 | 1/59 |
| AnxietyPsychiatric disorders | 2/58 | 4/59 |
| DiarrhoeaGastrointestinal disorders | 3/58 | 3/59 |
| AkathisiaNervous system disorders | 3/58 | 0/59 |
| VomitingGastrointestinal disorders | 1/58 | 3/59 |
| Upper respiratory tract infectionInfections and infestations | 2/58 | 3/59 |
ITT population
| Age, Continuous(years) | SD-809 | Placebo | Total |
|---|---|---|---|
| Mean | 55.9 ± 9.82 | 53.3 ± 10.64 | 54.6 ± 10.28 |
| Sex: Female, Male(Participants) | SD-809 | Placebo | Total |
|---|---|---|---|
| Female | 29 | 32 | 61 |
| Male | 29 | 27 | 56 |
| Ethnicity (NIH/OMB)(Participants) | SD-809 | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 11 | 15 |
| Not Hispanic or Latino | 53 | 47 | 100 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Race (NIH/OMB)(Participants) | SD-809 | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 19 | 14 | 33 |
| White | 37 | 44 | 81 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Education Level(Participants) | SD-809 | Placebo | Total |
|---|---|---|---|
| =12 years or fewer of formal education | 30 | 30 | 60 |
| >12 years of formal education | 28 | 29 | 57 |
| Weight(kg) | SD-809 | Placebo | Total |
|---|---|---|---|
| Mean | 86.94 ± 24.081 | 84.95 ± 20.975 | 85.94 ± 22.493 |
| Height(cm) | SD-809 | Placebo | Total |
|---|---|---|---|
| Mean | 169.23 ± 11.462 | 169.72 ± 10.098 | 169.48 ± 10.752 |
| Body Mass Index(kg/m^2) | SD-809 | Placebo | Total |
|---|---|---|---|
| Mean | 30.35 ± 7.926 | 29.45 ± 6.958 | 29.89 ± 7.435 |
4 further baseline measures are reported on the registry.
Ran from Jun 2014 to primary completion in May 2015, 11 months.
Results were first posted in Mar 2018, 2 years 10 months after primary completion. A results delay was requested in Apr 2017.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Deutetrabenazine
Auspex Pharmaceuticals, Inc. →